Apimeds Pharmaceuticals US (APUS) Other Non-Current Liabilities (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Other Non-Current Liabilities for 3 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities rose 675.54% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (up 675.54% YoY), and the FY2025 full-year result was $1.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities retreated to $1.4 million in Q2 2026 per APUS's latest filing, from $1.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $1.6 million in Q4 2025 and bottomed at $68878.0 in Q4 2023.
• Historically, Other Non-Current Liabilities has averaged $803211.2 across 3 years, with a median of $763527.0 in 2025.
• The widest YoY moves for Other Non-Current Liabilities: up 675.54% in 2026, down 675.54% in 2026.
• Over 3 years, Other Non-Current Liabilities stood at $68878.0 in 2023, then soared by 2247.5% to $1.6 million in 2025, then dropped by 16.34% to $1.4 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.4 million, $1.6 million, and $174413.0 for Q2 2026, Q4 2025, and Q2 2025 respectively.